CVSI
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment focuses on developing cannabinoids to treat medical indications. The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, California.
CV Sciences, Inc. (CVSI) is rated D+ (1.8/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Profitability (C+); its weakest is Momentum (D-). The rating has held at D+ for 56 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-07-29 | C+ (2.6) | D+ (1.7) | C+ (2.7) | D- (0.8) | D+ (1.5) | D+ (1.8) |
| 2025-06-30 | C+ (2.6) | D+ (1.7) | C+ (2.7) | F (0.7) | D+ (1.5) | D+ (1.8) |
| 2025-03-31 | C+ (2.7) | D+ (1.6) | C+ (2.7) | D- (0.9) | D+ (1.5) | C- (1.9) |
| 2024-12-31 | C+ (2.6) | C- (2.1) | C- (2.0) | D- (0.9) | D (1.5) | D+ (1.8) |
| 2024-09-30 | C+ (2.6) | D+ (1.8) | C (2.3) | D- (0.8) | D+ (1.5) | D+ (1.8) |